The Servier Group has always combined the manufacture of medicinal products with specialized industrial R&D teams. Consequently, industrial R&D activities take place at the Group’s production sites. In this way Servier can optimise flow management throughout the manufacturing process and control the quality of medicines.
In the last years, the Servier teams have stepped up their efforts to bring in a number of partnerships in the biotechnology field. This dynamic took on new impetus with the decision to develop biomedicines for clinical studies, predominantly in the field of oncology. Biomedicine production was kicked off in 2019 on the Gidy site in France.
Constantly striving to better meet patient needs Servier can rely on its industrial model, which offers high standards of quality across all production sites. The Group draws a considerable advantage from its network of 16 facilities around the world (Brazil, China, Egypt, France, Hungary, Ireland, Morocco, Nigeria, Poland, Russia and Spain) and reliable supply chain when it comes to supplying the 150 countries in which the Group’s medicines are prescribed.